A computational method for drug repositioning using publicly available gene expression data

BMC Bioinformatics. 2015;16 Suppl 17(Suppl 17):S5. doi: 10.1186/1471-2105-16-S17-S5. Epub 2015 Dec 7.

Abstract

Motivation: The identification of new therapeutic uses of existing drugs, or drug repositioning, offers the possibility of faster drug development, reduced risk, lesser cost and shorter paths to approval. The advent of high throughput microarray technology has enabled comprehensive monitoring of transcriptional response associated with various disease states and drug treatments. This data can be used to characterize disease and drug effects and thereby give a measure of the association between a given drug and a disease. Several computational methods have been proposed in the literature that make use of publicly available transcriptional data to reposition drugs against diseases.

Method: In this work, we carry out a data mining process using publicly available gene expression data sets associated with a few diseases and drugs, to identify the existing drugs that can be used to treat genes causing lung cancer and breast cancer.

Results: Three strong candidates for repurposing have been identified- Letrozole and GDC-0941 against lung cancer, and Ribavirin against breast cancer. Letrozole and GDC-0941 are drugs currently used in breast cancer treatment and Ribavirin is used in the treatment of Hepatitis C.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Computational Biology / methods*
  • Databases, Genetic*
  • Drug Repositioning / methods*
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Hepatitis C / genetics
  • Humans
  • Letrozole
  • Lung Neoplasms / genetics
  • Nitriles / therapeutic use
  • Triazoles / therapeutic use

Substances

  • Antineoplastic Agents
  • Nitriles
  • Triazoles
  • Letrozole